---
title: "EXCLUSIVE: Nano-Cap TC BioPharm Concludes Initial Cohort B Patient Dosing In Mid-Stage Leukemia Trial, Data Readout By End Of 2025"
date: "2025-02-10 22:15:24"
summary: "TC BioPharm&#39;s Phase 2B trial of TCB008 in AML progresses as the first Cohort B patient completes dosing. Enrollment continues, with data expected in 2025."
categories:
  - "benzinga"
lang:
  - "en"
translations:
  - "en"
tags:
  - "benzinga"
menu: ""
thumbnail: "https://www.benzinga.com/files/images/story/2025/02/10/TCBP.png"
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

TC BioPharm's Phase 2B trial of TCB008 in AML progresses as the first Cohort B patient completes dosing. Enrollment continues, with data expected in 2025.

[benzinga](https://www.benzinga.com/general/biotech/25/02/43592814/exclusive-nano-cap-tc-biopharm-concludes-initial-cohort-b-patient-dosing-in-mid-stage-leukemia-trial-data-readout-by-end-of-2025)
